Sugi Predict

Sugi Predict / Targets / ULK2

ULK2

Serine/threonine-protein kinase ULK2 · Q8IYT8 · ULK2 on Sugi Atlas →

7,727 patent compounds predicted against ULK2, 5,210 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3384338 SCHEMBL3384338 0.62 6/20
SCHEMBL1936257 SCHEMBL1936257 0.61 6/20
SCHEMBL3387242 SCHEMBL3387242 0.54 6/20
SCHEMBL3387443 SCHEMBL3387443 0.53 6/20
SCHEMBL3387297 SCHEMBL3387297 0.65 5/20
SCHEMBL1916411 SCHEMBL1916411 0.63 5/20
SCHEMBL1916412 SCHEMBL1916412 0.63 5/20
SCHEMBL1917078 SCHEMBL1917078 0.63 5/20
SCHEMBL1916420 SCHEMBL1916420 0.63 5/20
SCHEMBL1916421 SCHEMBL1916421 0.63 5/20
SCHEMBL1918690 SCHEMBL1918690 0.63 5/20
SCHEMBL1936755 SCHEMBL1936755 0.62 5/20
SCHEMBL3384329 SCHEMBL3384329 0.61 5/20
SCHEMBL1916344 SCHEMBL1916344 0.61 5/20
SCHEMBL3386041 SCHEMBL3386041 0.60 5/20
SCHEMBL1936754 SCHEMBL1936754 0.60 5/20
SCHEMBL3385947 SCHEMBL3385947 0.59 5/20
SCHEMBL2777601 SCHEMBL2777601 0.59 5/20
SCHEMBL1916892 SCHEMBL1916892 0.59 5/20
SCHEMBL1916894 SCHEMBL1916894 0.59 5/20

Clinical trials — most relevant to ULK2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Alpha Ketoglutarate Enhances Geroprotection In Surgery (AEGIS) PHASE4RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma PHASE2COMPLETED
A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer PHASE1/PHASE2COMPLETED
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma PHASE1/PHASE2COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy EARLY_PHASE1RECRUITING
Sirolomus Adjuvant Treatment of Focal Refractory Epilepsy (SATFRE) EARLY_PHASE1RECRUITING
Fasting, Exercise, and Diet to Activate Autophagy in Depression nanNOT_YET_RECRUITING
The Role of Fibroblast Activation in Uterine Fibroid nanCOMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Association of Autophagy-related Genes ,LncRNA and SNPs With Colorectal Cancer in Egyptian Population nanCOMPLETED
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection. nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Autophagy Bladder Cancer nanUNKNOWN
Time Course for Fasting-induced Autophagy in Humans nanWITHDRAWN
Intermittent Fasting for Pancreatitis nanNOT_YET_RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
The Impact of Intermittent Fasting on Human Metabolism and Cell Autophagy nanCOMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy nanRECRUITING
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED
Muscle Wasting in Cancer (MWIC) nanCOMPLETED
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ULK2 binder may also engage these)

ProteinNameSimilarity
Q9QY01 — 1.000 Q9QY01 →
O70405 — 1.000 O70405 →
A0M8T5 — 0.994 A0M8T5 →
MAP3K9 Mitogen-activated protein kinase kinase kinase 9 0.994 landscape →
Q09YG9 — 0.994 Q09YG9 →
Q3ULB5 — 0.994 Q3ULB5 →
Q6EE22 — 0.993 Q6EE22 →
Q9VLW2 — 0.993 Q9VLW2 →
Q2IBA2 — 0.993 Q2IBA2 →
Q09YK4 — 0.993 Q09YK4 →
Q8R0S2 — 0.993 Q8R0S2 →
Q09YJ3 — 0.993 Q09YJ3 →
Q09YM8 — 0.993 Q09YM8 →
Q60610 — 0.993 Q60610 →
Q5PRF9 — 0.993 Q5PRF9 →
Q2QLB3 — 0.993 Q2QLB3 →
Q00PJ1 — 0.992 Q00PJ1 →
A1X157 — 0.992 A1X157 →
Q5SSZ5 — 0.992 Q5SSZ5 →
Q6DN90 — 0.992 Q6DN90 →
Q68UT7 — 0.992 Q68UT7 →
P59281 — 0.992 P59281 →
Q76LL6 — 0.992 Q76LL6 →
Q07DV1 — 0.992 Q07DV1 →
Q80XS6 — 0.992 Q80XS6 →
O08774 — 0.992 O08774 →
Q07E15 — 0.992 Q07E15 →
O60292 — 0.992 O60292 →
Q3UJB9 — 0.992 Q3UJB9 →
Q8WZ74 — 0.992 Q8WZ74 →